← Search another drug
PatientPulse · by PatientPartner
Taltz ixekizumab
High confidence
~52 public patient conversations and reviews referenced (Drugs.com, WebMD, Inspire forums, patient blogs, Psoriasis Association forums)
Executive intelligence
The signal that moves starts & adherence
58%Positive sentiment in discussion
36,303FDA adverse-event reports
21%Flagged serious
61%Reports name female patients
Taltz's clearance story is its superpower, but the PsA segment rates it 6.3 vs 7.5 for plaque psoriasis -- a 1.2-point gap signaling an urgent joint-symptom expectation-setting gap that peer mentorship could close.
- Taltz earns near-miracle clearance language from long-term plaque psoriasis patients, with many reporting 95-100% clearance within weeks, creating powerful word-of-mouth advocacy in patient communities.
- Psoriatic arthritis patients rate Taltz a full 1.2 points lower than plaque psoriasis patients, driven by incomplete joint pain relief and a higher burden of systemic side effects including nausea and fatigue.
- Injection site pain and perceived needle size are the single most-cited friction point at initiation, yet patients who master the room-temperature and ice-prep technique consistently report the trade-off as acceptable.
- Insurance transitions, especially to Medicare, create a critical adherence cliff where previously $5/month patients face potential $1,600+/month costs, representing the highest-risk abandonment moment in the Taltz journey.